Investment analysts at StockNews.com started coverage on shares of Evoke Pharma (NASDAQ:EVOK – Get Rating) in a research report issued to clients and investors on Friday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.
Evoke Pharma Trading Down 3.4 %
Shares of EVOK opened at $1.87 on Friday. The company has a quick ratio of 5.71, a current ratio of 5.93 and a debt-to-equity ratio of 2.35. Evoke Pharma has a 12-month low of $1.37 and a 12-month high of $5.96. The firm has a market capitalization of $6.25 million, a PE ratio of -0.75 and a beta of 0.38. The stock’s fifty day simple moving average is $2.06 and its 200-day simple moving average is $2.51.
Evoke Pharma (NASDAQ:EVOK – Get Rating) last issued its quarterly earnings results on Tuesday, March 21st. The specialty pharmaceutical company reported ($0.53) earnings per share (EPS) for the quarter. Evoke Pharma had a negative net margin of 285.96% and a negative return on equity of 175.19%. The firm had revenue of $0.80 million for the quarter.
About Evoke Pharma
Evoke Pharma, Inc is a pharmaceutical company, which engages in the development of drugs for the treatment of gastrointestinal disorders and diseases. It also develops Gimoti, with promotility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women with diabetes mellitus.
Read More
- Get a free copy of the StockNews.com research report on Evoke Pharma (EVOK)
- Ralph Lauren’s Styled Dividend Is Still In Season
- Dollar Tree Falls As Theft Cuts Into Bottom Line
- Best Buy’s Comeback Is Still At Play, Earnings Call For Patience
- e.l.f. Beauty Has Giant Quarter, Shares Hit New High
- If You Can Only Pick One Stock For The Rest Of 2023, Pick Nvidia
Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
